CBIO
Crescent Biopharma
CBIO
CBIO
35 hedge funds and large institutions have $7.2M invested in Crescent Biopharma in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 16 reducing their positions, and 37 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
92% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 37
93% less capital invested
Capital invested by funds: $111M → $7.2M (-$103M)
Holders
35
Holding in Top 10
–
Calls
$675K
Puts
$44K
Top Buyers
| 1 | +$712K | |
| 2 | +$212K | |
| 3 | +$140K | |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$84.7K |
| 5 |
Two Sigma Advisers
New York
|
+$82.7K |
Top Sellers
| 1 | -$11.5M | |
| 2 | -$9M | |
| 3 | -$4.76M | |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$653K |
| 5 |
Millennium Management
New York
|
-$583K |